Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | IKBKB | O14920 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | CHUK | O15111 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14021629 | 0.92 | JAK2 (0.54) | PIK3CAPIK3CBPIK3CGJAK1AIMP2 | |
| SCHEMBL14021295 | 0.91 | AIMP2 (0.52) | SYKPIK3CAPIK3CBPIK3CGAIMP2 | |
| SCHEMBL14021310 | 0.91 | SYK (0.53) | SYKPIK3CAPIK3CBPIK3CGAIMP2 | |
| SCHEMBL8311018 | 0.89 | JAK2 (0.61) | SYKPIK3CAPIK3CBPIK3CGJAK1 | |
| SCHEMBL13590773 | 0.89 | PIK3CA (0.47) | PIK3CAPIK3CBPIK3CGJAK1AIMP2 | |
| SCHEMBL14021306 | 0.89 | SYK (0.54) | SYKPIK3CAPIK3CBPIK3CGJAK1 | |
| SCHEMBL4392408 | 0.89 | PIK3CA (0.51) | PIK3CAPIK3CBPIK3CGJAK1AIMP2 | |
| SCHEMBL14021308 | 0.88 | JAK2 (0.55) | SYKJAK1JAK2JAK3CDK2 | |
| SCHEMBL4063696 | 0.88 | JAK2 (0.50) | PIK3CAPIK3CBPIK3CGJAK1AIMP2 | |
| SCHEMBL8312148 | 0.88 | CDK1 (0.62) | PIK3CAPIK3CBPIK3CGAIMP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931322-B1 | IKK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MERCK SERONO SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2266561-A2 | IKK Inhibitors for the Treatment of Endometriosis | Merck Serono S.A. (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100069387-A1 | IKK Inhibitors for the Treatment of Endometriosis | MERCK SERONO SA (CH) | 2010-03-18 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1931322-A1 | IKK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | Laboratoires Serono SA (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030362-A1 | IKK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO SA. (CH) | 2007-03-15 | — | — | WO | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069387-A1 | IKK Inhibitors for the Treatment of Endometriosis | NFKBIA, IKBKG, IKBKE | SYK 640/4885PIK3CA 1177/4885PIK3CB 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.